Recent Updates
Recently added Catalysts
SEER Positive Sentiment Score: 70/100

Seer to Participate in Upcoming November Investor Conferences

Friday, November 8, 2024 2 min read
Key Takeaway: Seer, Inc. announced its participation in two upcoming investor conferences: the Guggenheim Inaugural Healthcare Innovation Conference in Boston and the Canaccord Genuity MedTech Forum in New York. These events include fireside chats scheduled for November 11th and November 21st, respectively. Seer is known for its Proteograph Product Suite, which offers a new approach to proteomic analysis. The company plans to provide live webcasts, making the presentations accessible to a wider audience.

Market Sentiment Analysis

POSITIVE FACTORS

  • Seer is participating in multiple investor conferences, enhancing visibility.
  • The company is presenting its innovative Platform for proteomics, potentially attracting interest.
  • Live webcasts and archived replays ensure broader accessibility for investors.

Full Press Release Details

REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:
Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA
Fireside chat on Monday, November 11th at 11:30 a.m. Eastern Time
Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY
Fireside chat on Thursday, November 21st at 10:00 a.m. Eastern Time
Live webcasts of the sessions will be available on the Investor section of Seer’s website at investor.seer.bio. Archived replays will be available on the company’s website following the conference.
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Frequently Asked Questions

What is Seer, Inc. known for?

Seer, Inc. specializes in a platform for proteomics, offering innovative solutions.

When is Seer's fireside chat at Guggenheim Conference?

The fireside chat will be on November 11th at 11:30 a.m. Eastern Time.

Where can I watch Seer's investor conference webcasts?

Webcasts can be accessed via the Investor section on Seer’s website.

What does Seer’s Proteograph Product Suite do?

The suite enables deep, unbiased proteomic analysis at scale efficiently.

Is Seer's Proteograph Product Suite for diagnostic use?

No, it is intended for research use only and not for diagnostic procedures.

Tags: SEER Viatris Investor Conferences Healthcare Seer proteomics investor conference Guggenheim Canaccord Genuity
Last updated: Nov 8, 2024